Isoniazid resistance in patients with Extrapulmonary Tuberculosis using line probe assay in a private multispecialty hospital in Bangalore, India

• DOI: 10.1016/j.ijmmb.2022.01.007
• Publication Date: 2022-02-22T13:08:35Z
• Authors: Sindhulina Chandr...; Sreeja Nair
• Keywords: 0301 basic medicine; 03 medical and health sciences; Tuberculosis, Multidrug-Resistant; Antitubercular Agents; Isoniazid; Humans; India; Tuberculosis; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Hospitals; 3. Good health

We aimed to study the rate of isoniazid (INH) resistance in Extrapulmonary Tuberculosis samples from a private care setting. A Line probe assay was performed on 74 culture isolates of Mycobacterium tuberculosis or directly on extrapulmonary samples received in our laboratory from 2018 to 2021. The INH mono-resistance among these extrapulmonary samples was 6.7%. (5 among 74) (95% CI: 1.04%-12.48%) Resistance to rifampicin was not detected. Increasing the availability and leveraging public private partnerships in hospitals for universal testing for INH resistance may increase detection of INH monoresistance in EP-TB and improve the strategy for TB elimination.